Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

GlobalData
February 15, 2015
142 Pages - SKU: GBDT5496718


Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


Additional Information

Deal Values in Pharmaceutical & Healthcare Industry Increased in Q4 2014

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014” report is an essential source of data and trend analysis on partnersh

More Pharmaceuticals Company reports by GlobalData

Orifarm Group AS - Strategic SWOT Analysis Review by GlobalData
Orifarm Group AS - Strategic SWOT Analysis Review- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report ...
Sareum Holdings plc (SAR) - Financial and Strategic SWOT Analysis Review by GlobalData
Sareum Holdings plc (SAR) - Financial and Strategic SWOT Analysis Review- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. ...
Par Pharmaceutical Companies, Inc. - Strategic SWOT Analysis Review by GlobalData
Par Pharmaceutical Companies, Inc. - Strategic SWOT Analysis Review- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The ...
Pacira Pharmaceuticals, Inc. (PCRX) - Financial and Strategic SWOT Analysis Review by GlobalData
Pacira Pharmaceuticals, Inc. (PCRX) - Financial and Strategic SWOT Analysis Review- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,500  
    Site License  USD 3,000  
    Global Site License  USD 4,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!